Conference Coverage

Be mindful of psoriasis/cutaneous T-cell lymphoma link


 

EXPERT OPINION FROM SDEF HAWAII DERMATOLOGY SEMINAR

Dr. Guy F. Webster

"Is the use of an anti-TNF agent going to increase that risk? The answer is that in all of the more than 2 million patients who’ve been treated with TNF inhibitors, there does not appear to be a statistical increase above the baseline risk," said Dr. Menter of Baylor University Medical Center, Dallas, and chair of the American Academy of Dermatology psoriasis guidelines committee.

SDEF and this news organization are owned by the same parent company. Dr. Menter, Dr. Gelfand, Dr. Webster, and Dr. Leonardi have received research funds and/or served as consultants to numerous pharmaceutical companies.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Psoriasis drug MK-3222 progresses through pipeline
Psoriasis Collection
Pregnancies after vasculitis diagnosis are at risk
Psoriasis Collection
Anti-TNF drugs don't boost risk of herpes zoster in inflammatory disorders
Psoriasis Collection
Apremilast improves psoriasis, shows strong safety profile
Psoriasis Collection
Systemic steroid prescriptions for psoriasis persist
Psoriasis Collection
Screen all psoriasis patients for hepatitis before immunosuppressive therapy
Psoriasis Collection
Consider treatment urgency when prescribing for psoriasis
Psoriasis Collection
All glucocorticoids linked to increased risk of VTE
Psoriasis Collection
Obesity interferes with TNF-alpha inhibitors in psoriatic arthritis
Psoriasis Collection
Exceeding 10 mg/day prednisone increased CV events in lupus
Psoriasis Collection